Labetuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Labetuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetcarcinoembryonic antigen
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]

Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.

This drug was developed by Immunomedics, Inc.

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab" (PDF). WHO Drug Information. 16 (1): 95. 2002.
  2. ^ "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.